NuPathe Inc.

NuPathe — JP Morgan Healthcare Conference January 2011

21 slides from NuPathe's conference presentation, Jan 10, 2011

  1. Slide 1: JP Morgan Healthcare Conference January 2011

    Slide 1: JP Morgan Healthcare Conference January 2011

    JP Morgan Healthcare Conference January 2011

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include,

  3. Slide 3: NuPathe Investment Highlights

    Slide 3: NuPathe Investment Highlights

    3 NuPathe Investment Highlights ZelrixTM - the first and only migraine patch 505(b)(2) NDA filed with FDA on October 29, 2010 PDUFA in 3Q11 expected Launch planned in 1H12 Migraine remains a large, but underserved, market Capital sufficient through approval and into launch Zelrix IP protection throu

  4. Slide 4: Harnessing the Power of Sumatriptan

    Slide 4: Harnessing the Power of Sumatriptan

    4 Harnessing the Power of Sumatriptan Zelrix applied during migraine attack Powered by SmartReliefTM Controlled delivery for four hours Applied to upper arm or thigh Single use, disposable

  5. Slide 5: Large Market: Triptans the Clear Leader

    Slide 5: Large Market: Triptans the Clear Leader

    5 Large Market: Triptans the Clear Leader 31 million migraine sufferers in the U.S. 1 - 4 migraines/month typical Triptans - clear market leader 123 million units in the U.S.* 72% of units and 97% of sales* * 12 months ended Oct 2010 ....yet, 4 out of 5 patients are looking for something new Total U

  6. Slide 6: Why a Patch for Migraine?

    Slide 6: Why a Patch for Migraine?

    6 Why a Patch for Migraine? * Overlap amongst patient types

  7. Slide 7: Nausea & Vomiting Impact Millions

    Slide 7: Nausea & Vomiting Impact Millions

    7 Nausea & Vomiting Impact Millions

  8. Slide 8: Zelrix: Designed to Address Shortcomings of Current Therapies

    Slide 8: Zelrix: Designed to Address Shortcomings of Current Therapies

    8 Therapeutic Level Zelrix: Designed to Address Shortcomings of Current Therapies Control provided by SmartRelief allows Zelrix to deliver efficacy with minimal triptan AEs

  9. Slide 9: Zelrix Delivers... Predictability and Reliability

    Slide 9: Zelrix Delivers... Predictability and Reliability

    9 Zelrix Delivers... Oral 100mg Sumatriptan Nasal Sumatriptan Zelrix Predictability and Reliability

  10. Slide 10: Pivotal Phase Data Confirms Value

    Slide 10: Pivotal Phase Data Confirms Value

    10 p < 0.0001 East 0.53 West 0.29 Pivotal Phase 3 Data Confirms Value Photophobia Free Phonophobia Free Pain Free - Primary Nausea Free Pain Relief p = 0.0092 East 0.18 West 0.09 p < 0.0001 East 0.84 West 0.63 p = 0.0028 East 0.51 West 0.36 p = 0.0002 East 0.55 West 0.39 Data at 2 hours Zelrix n = 2

  11. Slide 11: Rapid and Sustained Pain Relief

    Slide 11: Rapid and Sustained Pain Relief

    11 Rapid and Sustained Pain Relief Rapid pain relief 38% more Zelrix patients than placebo at 30 minutes^ Significant and comparable to oral and nasal triptans at one hour Sustained pain relief 34% of Zelrix patients compared to 21% of placebo (p=0.0015) from 2 to 24 hours ^ Not statistically signif

  12. Slide 12: Favorable Adverse Event Profile

    Slide 12: Favorable Adverse Event Profile

    12 Favorable Adverse Event Profile Application site events were typical of patches Majority were mild in intensity and transient Minimal incidence of triptan adverse events Compared to product labeling for oral (12 - 14%) and injection (47%)

  13. Slide 13: Positive Long-Term Data for Zelrix

    Slide 13: Positive Long-Term Data for Zelrix

    13 Positive Long-Term Data for Zelrix Two 12 month trials (NP101-008, NP101-009) NP101-008: top-line efficacy and safety results Strong, consistent efficacy within two hours Headache pain relief for 58% of migraines treated Headache pain free for 24% of migraines treated Nausea free for 79% of migra

  14. Slide 14: Setting the Stage for Commercialization

    Slide 14: Setting the Stage for Commercialization

    14 Setting the Stage for Commercialization Commercial infrastructure Gradual build - hire core commercial team prior to FDA approval Sales force of ~100 to be hired after approval US partnership NDA filing - important milestone To expand product reach and revenue Manufacturing scale-up Commercial eq

  15. Slide 15: Concentrated, High Volume Target Audience

    Slide 15: Concentrated, High Volume Target Audience

    15 15 Concentrated, High Volume Target Audience Launch (~100 Sales Reps) 10.5K physicians Neurologists, headache specialists Average >500 migraine Rx's/year Expansion Opportunity 31K physicians Primary care physicians Average ~200 migraine Rx's/year

  16. Slide 16: Zelrix Offers Value to Managed Care

    Slide 16: Zelrix Offers Value to Managed Care

    16 Zelrix Offers Value to Managed Care Market research with payers covering >120 million lives Payers recognize Zelrix value proposition Unmet needs exist in migraine Expect broad formulary access for Zelrix - Tier 2 potential Well-positioned after patient trial with oral At least parity to other br

  17. Slide 17: Pipeline Addresses Unmet Needs in CNS

    Slide 17: Pipeline Addresses Unmet Needs in CNS

    17 Pipeline Addresses Unmet Needs in CNS Pipeline powered by proprietary technology platforms SmartRelief - Zelrix LAD(tm) - NP201 and NP202 1. 505(b)(2) NDA submitted October 29, 2010 2. 505(b)(2)

  18. Slide 18: LAD: Improved Treatment Through Continuous Delivery

    Slide 18: LAD: Improved Treatment Through Continuous Delivery

    18 LAD: Improved Treatment Through Continuous Delivery NP201: Long term delivery of ropinirole to treat the signs and symptoms of Parkinson's disease Designed to address tolerability and need for consistent long-term efficacy Current status: Preclinical POC study complete - return to normal function

  19. Slide 19: Financial Strength to Execute

    Slide 19: Financial Strength to Execute

    19 Financial Strength to Execute Strong cash position $47 million at September 30, 2010 Cash sufficient through approval and into launch of Zelrix Efficient use of resources Near-term revenues with launch of Zelrix in 2012

  20. Slide 20: Demonstrated Execution Post-IPO

    Slide 20: Demonstrated Execution Post-IPO

    20 Demonstrated Execution Post-IPO Completion of PK study of Zelrix in young & elderly Completion of PK study of Zelrix to evaluate bioavailability Completion of study of Zelrix to evaluate cumulative skin irritation Zelrix NDA filing Completion of long-term safety study Zelrix NDA acceptance NP201

  21. Slide 21

    Slide 21

Source: SEC EDGAR · 8-K filed Jan 10, 2011

More decks from NuPathe Inc.